Evidence map›Paper›PMID 42290237›Full record

ArticleDevelopment (Cambridge, England)2026

Human vein-to-artery endothelial cell fate transition is driven by VEGF/ERK activation and PI3K inhibition.

Zhainib A Amir-Ugokwe, Alanna L Pyke, Emily Trimm, Meenakshi Chakraborty, Xiaochen Fan, Lay Teng Ang, Kyle M Loh, Kristy Red-Horse

Abstract read
PubMed Publisher
In one paragraph

Article in Development (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Zhainib A Amir-UgokweDepartment of Biology, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-1429-1729
Alanna L PykeDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Emily TrimmDepartment of Biology, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-8610-3075
Meenakshi ChakrabortyDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-7681-5634
Xiaochen FanDepartment of Biology, Stanford University, Stanford, CA 94305, USA.ORCID 0009-0007-3334-7122
Lay Teng AngInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6783-4662
Kyle M LohInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-8042-0149
Kristy Red-HorseDepartment of Biology, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-1541-601X

Funding

Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9M
Scientific Core: Perturb-seq library generation, sequencing, and data analysisP01HL180323 · NHLBI · STANFORD UNIVERSITY · PI THOMAS QUERTERMOUS · 2025 to 2026
$7.1M
Mechanotransduction and transcriptional regulation during artery developmentR01HL128503 · NHLBI · STANFORD UNIVERSITY · PI Mary Red-Horse · 2015 to 2026
$5.8M
Intersecting clinical, genomic, and experimental investigation to understand the mechanisms and impact of coronary artery patterningR01HL171326 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI Themistocles L Assimes, Mary Red-Horse · 2024 to 2026
$2.0M
Additional VenturesAdditional Ventures Expansion AwardAmaranth FoundationAmerican Heart Association 25PRE1375905Bladder Cancer Advocacy NetworkBreakthrough Institute Breakthrough T1D Northern California Center of ExcellenceBreakthrough T1DDavid and Lucile Packard FoundationDonald E. and Delia B. Baxter FoundationGilbert Family FoundationHoward Hughes Medical InstituteHuman Frontier Science Program RGY0069/2019Ludwig Institute for Cancer ResearchNIH HHS P01HL180323NIH HHS R01HL128503NIH HHS R01HL171326NIH HHS T32GM007276Pew Charitable TrustsSiebel Stem Cell InstituteStanford Maternal and Child Health Research InstituteStanford Maternal and Child Health Research Institute Chambers Family Foundation Innovation GrantStanford University
6 · The paper itself

Abstract

Artery endothelial cells (ECs) arise through different pathways, including differentiation from mesodermal cells (vasculogenesis) or from already established vein or capillary plexus ECs (angiogenesis), the latter being most common during embryonic development and regeneration. Understanding the vein-to-artery (v2a) transition could improve revascularization therapies, but progress is limited by a lack of human models. Here, we develop a human pluripotent stem cell differentiation protocol that models the v2a EC conversion. Comparing v2a and mesoderm-to-artery transcriptomes with publicly available single-cell RNA sequencing data from human embryos showed they reflected angiogenesis- and vasculogenesis-derived artery ECs, respectively. This reductionist system revealed that VEGF activation alongside PI3K inhibition was sufficient for vein ECs to acquire arterial identity within 48 h. In summary, we model a critical step in vascular development and define the minimal signals required for artery differentiation from veins, providing a framework to promote this conversion in revascularization or therapeutic contexts.

Indexed as

ArteriesEndothelial CellsExtracellular Signal-Regulated MAP KinasesPhosphoinositide-3 Kinase InhibitorsVascular Endothelial Growth Factor AVeinsAngiogenesisCell DifferentiationCell LineageHumansMesodermNeovascularization, PhysiologicPhosphatidylinositol 3-KinasesPluripotent Stem CellsExtracellular Signal-Regulated MAP KinasesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsVascular Endothelial Growth Factor AVEGFA protein, humanAngiogenesisCell fate switchEndothelial differentiationHuman pluripotent stem cellsVasculogenesisVein-to-artery endothelial conversion

Identifiers

PMID42290237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.